# A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

> **NCT04611724** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 35 (estimated)

## Conditions studied

- Urachal Cancer

## Interventions

- **DRUG:** FOLFIRINOX

## Key facts

- **NCT ID:** NCT04611724
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2020-11-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04611724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04611724, "A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04611724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*